IP Library Patent Application 15711205
Patent Application
App. No. 15/711,205

METHODS OF TREATING CANCER

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/711,205
Abstract

The present invention relates to methods of treating or preventing cancer in a subject in need thereof comprising administering a therapeutically effective amount of a compound of the invention.

Claims (15)

1 . A method of treating or preventing cholangiocarcinoma in a subject in need thereof comprising administering a therapeutically effective amount of a FXR agonist selected from Compound 1 or 2:

or a pharmaceutically acceptable salt or amino acid conjugate thereof.

2 - 4 . (canceled)

5 . The method of claim 1 , wherein the FXR agonist is Compound 1 or a pharmaceutically acceptable salt thereof.

6 . The method of claim 5 , wherein the FXR agonist is the sodium salt of Compound 1.

7 . The method of claim 5 , wherein the FXR agonist is the N N-diethylethaneamine salt of Compound 1.

8 . The method of claim 1 , wherein the FXR agonist is Compound 2 or a pharmaceutically acceptable salt or amino acid conjugate thereof.

9 . The method of claim 8 , wherein the FXR agonist is the glycine conjugate of Compound 2.

10 . The method of claim 8 , wherein the FXR agonist is the taurine conjugate of Compound 2.

11 . The method of claim 8 , wherein the FXR agonist is the sarcosine conjugate of Compound 2.

12 . A method of treating or preventing cholangiocarcinoma in a subject in need thereof comprising administering a pharmaceutical composition comprising a therapeutically effective amount of FXR agonist selected from Compound 1 or 2:

or a pharmaceutically acceptable salt or amino acid conjugate thereof and a pharmaceutically acceptable excipient.

13 . A kit for treating or preventing cholangiocarcinoma in a subject in need thereof comprising Compound 1 or Compound 2:

or a pharmaceutically acceptable salt or amino acid conjugate thereof.

14 - 16 . (canceled)

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Jan 4, 2024
From: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 066662/0210 →
CHANGE OF ADDRESS Recorded Aug 22, 2022
From: INTERCEPT PHARMACEUTICALS, INC.
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 061297/0990 →
SECURITY INTEREST Recorded Aug 18, 2021
From: INTERCEPT PHARMACEUTICALS, INC.
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 057650/0772 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2019
From: MOSCHETTA, ANTONIO
To: INTERCEPT PHARMACEUTICALS, INC
Reel/Frame 048619/0957 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2019
From: BANALES ASURMENDI, JESUS MARIA; FERNANDEZ DE PIEROLA, LUIS BUJANDA; PERUGORRIA MONTIEL, MARIA JESUS; AZPARREN, OIHANE ERICE
To: INTERCEPT PHARMACEUTICALS, INC
Reel/Frame 048153/0597 →